首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 78 毫秒
1.
脑腹侧被盖区微量注射溴隐亭对伏隔核DOPAC含量的影响   总被引:1,自引:0,他引:1  
钱朝霞  张海光 《生理学报》1993,45(5):479-485
本工作在戊巴比妥钠麻醉的SD雄性大鼠上进行。结果表明:左侧腹侧被盖区(VTA)微量注射多巴胺(DA)受体激动剂溴隐亭(2.5μg/0.5μl,n-5)后,用微分脉冲伏安法(DPV)测定同侧伏隔核中多巴胺代射产物—3、4双羟苯乙酸(DOPAC),峰值明显增高,注生50min达到对照值的128%(P<0.01),注后80min达到最高峰,为对照值的143%(P<0.01),作用的持续时间约2h,在注后  相似文献   

2.
大鼠中脑腹侧被盖区在睡眠-觉醒调节中的作用   总被引:1,自引:0,他引:1  
本实验在31只清醒自由行动的雄性SD大鼠进行。结果如下:(1)双侧中脑腹侧被盖区(VTA)微量注射3.3nmol溴隐亭后第2—3h觉醒时间显著增加(P<0.01);6.6nmol溴隐亭有类似效果;0.66和1.33nmol溴隐亭无明显作用。(2)同样方法VTA微量注射2nmol和4nmolSCH23390后第2—3h觉醒时间明显减少(分别为P<0.01和P<0.05),但注射3.4nmol舒必利则无效。(3)红藻氨酸(0.3μg)双侧VTA注后一周,大鼠白天觉醒减少,夜间无明显变化。以上结果表明溴隐亭微量注射到VTA可能通过D1受体使多巴胺神经元活动增加而产生致觉醒作用;另外VTA中DA神经元对于维持日间的觉醒可能有紧张性作用。  相似文献   

3.
6-羟多巴胺纹状体内注射制作大鼠帕金森病模型的研究   总被引:11,自引:0,他引:11  
目的 为拓宽6-OHDA损毁多巴胺能神经元所制备大鼠帕金森病模型的应用范围,采用多位点纹状体内注入6-OHDA的途径来制备模型。方法 研究用SD大鼠,两个针道内四点定位注射,每点注射3μg/μ16-OHDA3μl。结果 术后两周出现缓慢旋转,4周旋转行为达到7转/分并保持稳定;形态学染色可见损毁1周后注射侧黑质酪氨酸羟化酶免疫组化阳性细胞减少20%,2周后减少38%,3~4周减少70%以上,6周后损伤趋缓。高效液相-电化学法活体检测纹状体内多巴胺的代谢产物3、4-二羟基苯乙酸(DOPAC)和高香草酸(HVA),发现注射侧和非注射侧相比含量分别下降98.33%和96.05%;组织匀浆检测损毁侧黑质多巴胺含量下降了73%以上,3、4-二羟基苯乙酸(DOPAC)含量下降60%。结论 纹状体内注射6-OHDA能够制备帕金森病大鼠模型。  相似文献   

4.
大鼠中脑腹侧被盖区在睡眠—觉醒调节中的作用   总被引:1,自引:0,他引:1  
张文慧  钱朝霞 《生理学报》1995,47(2):195-200
本实验在31只清醒自由行动的雄性SD大鼠进行。结果如下:(1)以侧中脑腹侧被盖区(VTA)微量注射3.3nmol溴亭后第2-3h觉醒时间显著增加(P<0.01);6.6nmol溴隐亭有类似效果;0.66和1.33nmol溴隐亭无明显作用。(2)同样方法VTA微量注射2nmol和4nmolSCH23390后第2-3h觉醒时间明显减少(分别为P<0.01和P<0.05),但注射3.4nmol舒必利则无  相似文献   

5.
家免63只,用乌拉坦(700mg/kg)和氯醛醣(35mg/kg)静脉麻醉,三碘季铵酚制动,在人工呼吸下进行实验。用电刺激下丘脑近中线区的方法诱发定性期前收缩(HVE)。双侧延髓腹侧区内微量注射吗啡(5μg 溶于0.5—1μl 中)可抑制 HVE。在双侧延髓腹侧区微量注射纳洛酬(2μg 溶于0.5—1μl 中)能阻断电刺激中缝核尾端或中缝核尾端内微量注射 L-谷氨酸钠(50mmol/L,0.5—1μl)对 HVE 的抑制效应,也能减少或消除刺激腓深神经对 HVE 的抑制作用。上述结果提示,延髓腹侧部阿片受体的激活可抑制 HVE;另外,腓深神经传入冲动也可能通过中缝核尾端激活延髓腹侧区的阿片受体而抑制 HVE。  相似文献   

6.
家兔62只,用乌拉坦(700mg/kg)和氯醛醣(35mg/kg)静脉麻醉,三碘季铵酚制动,在人工呼吸下进行实验。用电刺激下丘脑近中线区的方法诱发室性期前收缩(HVE)。静脉注射安定(0.5mg/kg)可降低基础血压(BP),减弱刺激下丘脑引起升压反应(指收缩压峰值SBP_(max))和减少HVE。在双侧延髓腹外侧头端区(rVLM)微量注射氟安定(200μg溶于0.5μl中),γ-氨基丁酸(GABA)(6μg溶于0.5μl中)均能降低BP、SBP_(max)和减少HVE,若微量注射印防己毒素(7.5μg溶于0.5μl中)则可使BP上升并增多HVE。而于双侧延髓腹外侧尾端区(cVLM)微量注射同样剂量氟安定、GABA则无上述反应。安定降低BP、SBP_(max)和减少HVE的作用可被双侧rVLM区微量注射GABA受体拮抗剂荷包牡丹碱(3μg溶于0.5μl中)或印防己毒素所消除,但在双侧rVLM区微量注射甘氨酸受体拮抗剂士的宁(1μg溶于0.5μl中)、阿片受体拮抗剂纳洛酮(0.5μg溶于0.5μl中)、胆碱能阻断药阿托品(0.25μg溶于0.5μl中)、东莨菪碱(1.5μg溶于0.5μl中)后仍然存在。 上述结果提示,在双侧rVLM应用GABA受体拮抗剂可消除安定降低BP、SBP_(max)和减少HVE的作用,安定降低BP、SBP_(max)和减少HVE的作用可能通过GABA这一中间环节,而胆碱能受体、阿片受体、甘氨酸受体可能不起重要作用。  相似文献   

7.
实验用Wistar大鼠62只,采用束缚加悬吊的方法引起应激性高血粘度和血压升高。结果观察到,清醒大鼠束缚加悬吊二天可引起应激性高血粘度和血压升高。第四脑室内注射5-羟色胺(5-HT25μg/10μl)或在双侧延髓腹外侧区头端(rVLM)微量注射5-HT(4μg/0.5μl/每侧)均可抑制应激性高血粘度和血压升高,若预先在双侧rVLM微量注射5-HT受体阻断剂肉桂硫胺(4μg/0.5μl/每侧)后再在第四脑室或延髓腹外侧区内注入上述同剂量的5-MT,则5-HT降低应激性高血粘度和血压升高的作用消失。看来上述5-HT的作用是通过rVLM内5-HT受体的激活来实现的。  相似文献   

8.
兔廷髓中线区微量注射5-羟色胺(10μg溶于2μl中)或吗啡(10μg溶于2μl中)可减少刺激下丘脑诱发的室性期前收缩(HVE),微量注射肉桂硫胺(4μg溶于2μl中)或纳络酮(4μg溶于2μl中)可在多数动物中引起 HVE 短时内增多。先微量注射肉桂硫胺(2μg溶于1μl中)再微量注射吗啡(10μg溶于1μl中)或先微量注射纳络酮(2μg溶于1μl中)再微量注射5-羟色胺(10μg溶于1μl中),均不能明显影响吗啡、5-羟色胺对 HVE 的抑制效应。延髓中线区微量注射去甲肾卜腺素(2—4μg溶于2—4μl中)不能象在中脑中央灰质微量注射那样使 HVE 增多。对照组动物延髓中线区微量注射生理盐水(2μl)对 HVE 无明显影响。结果提示:延髓中线区5-羟色胺受体和阿片受体的活动对 HVE 有抑制作用。  相似文献   

9.
于14条清醒狗静脉内匀速注射硝普钠造成急性实验性低血压时(动脉收缩压从131±6mmHg 降至94±4mmHg),在中脑中央灰质、下丘脑腹内侧核区、中脑中缝核旁网状结构微量注射东莨菪碱20μg(溶于2μl生理盐水),可以阻断电针的升压作用。如果在低血压清醒狗中于上述中枢部位微量注射乙酰胆碱(ACh)200μg(溶于2μl生理盐水),可引起血压明显回升(收缩压从94±4mmHg 升到110±6mmHg,P<0.01),持续约10min。实验结果表明:用舒血管药物造成实验性低血压时,电针引起的升压作用与中脑中央灰质、下丘脑腹内侧核区、中脑中缝核旁网状结构等部位的胆碱能 M 受体的激活有关。  相似文献   

10.
摘要 目的:研究小鼠中脑腹侧被盖区(VTA)多巴胺能神经元接受的全脑输入性上游投射及其输出性下游投射,解析其全脑上下游神经环路连接。方法:用立体定位仪将辅助病毒AAV-EF1a-DIO-GT和AAV-EF1a-DIO-G的混合液(1:1)注射到DAT-cre转基因小鼠的VTA脑区,2周后将重组狂犬病毒(RV)EnVA-RV-mCherry微注射到VTA脑区,1周后RV病毒完成逆向跨突触感染并充分表达荧光蛋白,全脑冰冻切片,用全自动扫描荧光显微镜全脑拍片。用立体定位仪将顺行示踪病毒AAV-EF1a-DIO-GFP微注射到DAT-cre转基因小鼠的VTA脑区,2周后待病毒及荧光蛋白充分表达后,全脑冰冻切片,VTA区脑片用TH抗体行免疫荧光染色,全自动扫描荧光显微镜全脑拍片。结果:狂犬病毒逆向跨单级突触示踪结果显示,全脑许多脑区核团神经元表达RV病毒携带的红色荧光蛋白,主要包括前脑皮层、纹状体、伏隔核、下丘脑视前区、外侧下丘脑、下丘脑室旁核、杏仁核、腹侧被盖区、黑质、中缝背核、臂旁核、缰核。顺行示踪病毒结果显示,表达绿色荧光蛋白的纤维投射主要集中在内侧前额叶皮层、纹状体、伏隔核、背外侧隔核、杏仁核、外侧下丘脑几个脑区。结论:VTA多巴胺能神经元的上游输入性投射广泛的分布于全脑,包括前脑皮层、基底神经节区、下丘脑区、边缘系统、中脑的许多核团都向其发出纤维投射。VTA多巴胺神经元的下游输出性投射主要集中在基底神经节的伏隔核和纹状体,内侧前额叶皮层及下丘脑也有一定投射。  相似文献   

11.
12.
13.
14.
It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.  相似文献   

15.
16.
Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.  相似文献   

17.
Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.  相似文献   

18.
肝癌中HBV和HCV基因和抗原的分布及意义   总被引:1,自引:0,他引:1  
采用原位分子杂交方法检测HCV RNA及HBV X基因;采用免疫组织化学方法研究HCV核心抗原,非结构区C33c抗原及HBxAg在肝细胞肝癌中的定位及分布.结果表明(1)HCV RNA、HBV X基因在肝细胞肝癌组织检出率分别为40%(55/136)和82%(112/136).HCV RNA定位于癌细胞的胞浆内,阳性细胞呈散在、灶状及弥漫分布三种形式;HBV X基因在肝癌细胞中的分布呈胞浆型、核型及核浆型,阳性细胞也呈上述三种分布形式;(2)HCV C33c抗原、核心抗原在肝细胞肝癌中的阳性率为81%(133/164)及86%(141/164).C33c抗原定位于癌细胞及肝细胞的胞浆内;核心抗原既定位于癌细胞核中,又可定位于胞浆中.C33c抗原阳性细胞以灶状分布为主;而核心抗原阳性细  相似文献   

19.
20.
For a plant selection model with frequency-independent viabilities, fertilities and selfing rates, it is shown that apart from global fixation, for certain parameter combinations a protected polymorphism and facultative fixation (either allele may become fixed according to initial frequencies) may both occur. Facultative fixation requires different selling rates for the dominant and recessive type. Protection of the polymorphism requires resource allocation for male and female function. In this connection the problem of purely genetically caused population extinction is discussed.
For general frequency dependence and regular segregation, the chances for establishment of a completely recessive gene are compared to those of a completely dominant gene. It is proven that the process of establishment of the recessive gene, despite a fitness advantage, may be considerably endangered by drift effects if random mating prevails. The recessive gene may reach the same effectivity in establishment as a dominant gene, only if the recessive homozygote mates exclusively with its own type during the period of establishment.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号